Evidence map›Paper›PMID 26574544›Full record

ArticleThe Journal of biological chemistry2016

Proteolytic Processing of Neuregulin 1 Type III by Three Intramembrane-cleaving Proteases.

Daniel Fleck, Matthias Voss, Ben Brankatschk, Camilla Giudici, Heike Hampel, Benjamin Schwenk, Dieter Edbauer, Akio Fukumori, Harald Steiner, Elisabeth Kremmer and 5 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Physiological functions of SPP/SPPL intramembrane proteases.Cellular and molecular life sciences : CMLS · 2020
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Daniel FleckFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich.
Matthias VossFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich.
Ben Brankatschkthe Department of Molecular Neurobiology, Clinic for Psychiatry, Ludwig-Maximilians-University Munich, 80336 Munich.
Camilla GiudiciFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich.
Heike HampelFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich.
Benjamin Schwenkthe German Center for Neurodegenerative Diseases (DZNE), Munich, 81377 Munich.
Dieter Edbauerthe German Center for Neurodegenerative Diseases (DZNE), Munich, 81377 Munich, the Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, and.
Akio Fukumorithe German Center for Neurodegenerative Diseases (DZNE), Munich, 81377 Munich.
Harald SteinerFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich, the German Center for Neurodegenerative Diseases (DZNE), Munich, 81377 Munich.
Elisabeth Kremmerthe Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, and the Institute of Molecular Immunology, Helmholtz Center Munich, 81377 Munich, Germany.
Martina Haug-KröperFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich.
Moritz J Rossnerthe Department of Molecular Neurobiology, Clinic for Psychiatry, Ludwig-Maximilians-University Munich, 80336 Munich.
Regina FluhrerFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich, the German Center for Neurodegenerative Diseases (DZNE), Munich, 81377 Munich.
Michael WillemFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich, Michael.Willem@mail03.med.uni-muenchen.de.
Christian HaassFrom the Biomedical Center, Biochemistry, Ludwig-Maximilians-University Munich, 81377 Munich, the German Center for Neurodegenerative Diseases (DZNE), Munich, 81377 Munich, the Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, and christian.haass@mail03.med.uni-muenchen.de.
Ludwig-Maximilians-Universität München · DEGerman Center for Neurodegenerative Diseases · DEHelmholtz Zentrum München · DEMunich Cluster for Systems Neurology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous membrane-bound proteins undergo regulated intramembrane proteolysis. Regulated intramembrane proteolysis is initiated by shedding, and the remaining stubs are further processed by intramembrane-cleaving proteases (I-CLiPs). Neuregulin 1 type III (NRG1 type III) is a major physiological substrate of β-secretase (β-site amyloid precursor protein-cleaving enzyme 1 (BACE1)). BACE1-mediated cleavage is required to allow signaling of NRG1 type III. Because of the hairpin nature of NRG1 type III, two membrane-bound stubs with a type 1 and a type 2 orientation are generated by proteolytic processing. We demonstrate that these stubs are substrates for three I-CLiPs. The type 1-oriented stub is further cleaved by γ-secretase at an ϵ-like site five amino acids N-terminal to the C-terminal membrane anchor and at a γ-like site in the middle of the transmembrane domain. The ϵ-cleavage site is only one amino acid N-terminal to a Val/Leu substitution associated with schizophrenia. The mutation reduces generation of the NRG1 type III β-peptide as well as reverses signaling. Moreover, it affects the cleavage precision of γ-secretase at the γ-site similar to certain Alzheimer disease-associated mutations within the amyloid precursor protein. The type 2-oriented membrane-retained stub of NRG1 type III is further processed by signal peptide peptidase-like proteases SPPL2a and SPPL2b. Expression of catalytically inactive aspartate mutations as well as treatment with 2,2'-(2-oxo-1,3-propanediyl)bis[(phenylmethoxy)carbonyl]-l-leucyl-l-leucinamide ketone inhibits formation of N-terminal intracellular domains and the corresponding secreted C-peptide. Thus, NRG1 type III is the first protein substrate that is not only cleaved by multiple sheddases but is also processed by three different I-CLiPs.

Indexed as

ProteolysisAmino Acid SequenceAmino Acid SubstitutionAnimalsAspartic Acid EndopeptidasesCell MembraneC-PeptideHEK293 CellsHumansMolecular Sequence DataMutationNeuregulin-1NeuronsPeptide HydrolasesPeptidesPolymorphism, Single NucleotideAspartic Acid EndopeptidasesC-PeptideNeuregulin-1Peptide HydrolasesPeptidesADAMAlzheimer diseaseamyloid-β (AB)neurodegenerationβ-secretase 1 (BACE1)γ-secretase

Identifiers

PMID26574544
PMCPMC4697167
OpenAlexW2221662528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.